Please provide your email address to receive an email when new articles are posted on . An epithelium-on cross-linking procedure from Glaukos delivers oxygen to the eye during treatment. In a study, ...

Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

Please provide your email address to receive an email when new articles are posted on . Epioxa is the first epithelium-on cross-linking procedure approved in the U.S. Glaukos plans for Epioxa to be ...

Patients in Somerset with keratoconus, an eye condition that causes blurred vision and sensitivity to light, can now access ...

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...